Vertex Pharma (VRTX) Tops Q2 EPS by 19c; Raises Outlook

Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.94, $0.19 better than the analyst estimate of $0.75. Revenue for the quarter came in at $750 million versus the consensus estimate of $680.98 million.

Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion; reiterates full-year 2018 combined non-GAAP R&D and SG&A expense guidance of $1.50 to $1.55 billion-

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• INVO Fertility (IVF) Tops Q2 EPS by 105c